DisperSol Technologies, LLC, a specialty pharmaceutical company, has appointed Tim Scott as president and chief executive officer of the company. The company has also changed its name to AustinPx™, Pharmaceutics and Manufacturing, to better reflect the company’s new direction as a contract development and manufacturing organization (CDMO). Mr. Scott also joins the board of directors of AustinPx.
 
The hiring of Mr. Scott and the company name change are part of a shift in the focus of the company that first developed KinetiSol technology, an amorphous dispersion technology for improving drug bioavailability. The company will now provide pharmaceutical chemistry services including analytical and formulation development and cGMP manufacturing at its site in Austin, Texas.
 
Mr. Scott was the co-founder and president of Pharmatek Laboratories from 1999 until 2016, when he sold the company to Catalent Pharma Solutions. He currently serves as board chair of Biocom, a trade organization supporting 2,000 life science companies. Mr. Scott also serves on the Medical Research Advisory Committee for the Conrad Prebys Foundation, providing grants to innovative research in the health sciences.
 
“I can think of no one better to lead the transformation of AustinPx than Tim,” said Shaun Kirkpatrick, President at Research Corporation Technologies and board chair of AustinPx. “He brings a wealth of experience in building a contract development and manufacturing business, and he has strong connections throughout the industry. We are delighted to have his leadership as we build AustinPx into a world class CDMO.”
 
KinetiSol is an advanced technology that transforms active pharmaceutical ingredients into amorphous solid dispersions, thereby enhancing the physiochemistry and PK of drugs. KinetiSol provides a broader formulation design space and a more efficient scale-up.